<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02833415</url>
  </required_header>
  <id_info>
    <org_study_id>STU-012015-064</org_study_id>
    <secondary_id>K23DK106520</secondary_id>
    <nct_id>NCT02833415</nct_id>
  </id_info>
  <brief_title>Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging</brief_title>
  <official_title>Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a clinical study to investigate the gluconeogenesis pathway related to visceral
      adipose tissue (VAT) in obese individuals without type 2 diabetes and the effects of
      empagliflozin (EMPA) on glucose homeostasis in viscerally-obese individuals using functional
      studies of glycerol metabolism in hepatic gluconeogenesis using a well-validated nuclear
      magnetic resonance (NMR) spectroscopy platform.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetes mellitus type II is the consequence of insulin resistance and pancreatic beta cell
      failure resulting from a variety of metabolic insults, one of which is excess body
      adiposity/obesity. In the diabetic individual, hepatic gluconeogenesis may go uninhibited due
      to failure of the body's normal feedback mechanisms to appropriately incorporate glucose into
      cells via insulin signaling, leading to excess gluconeogenesis and hyperglycemia. The
      substrate for this excess glucose derives from multiple sources in the liver including
      dietary glycerol, adipose-derived glycerol from lipolysis, and substrates from the citric
      acid cycle. In the normal state, lipolysis is maintained at a steady state in equilibrium
      between stored dietary triglycerides and free fatty acids. However, in situations of
      triglyceride excess (e.g. in the obese state), lipolysis may become overactive resulting in
      increased free fatty acids and adipose-derived glycerol. This excess glycerol drives hepatic
      gluconeogenesis and is incorporated into glucose and released into the blood, leading to
      hyperglycemia, and ultimately diabetes and its clinical sequelae.

      A popular hypothesis linking visceral fat with excess gluconeogenesis is delivery of glycerol
      arising from mesenteric triglyceride turnover directly into the portal circulation and to the
      liver. Glycerol is a primary substrate for gluconeogenesis in the liver. Under normal
      conditions, hepatic gluconeogenesis begins from glycerol ingested in the diet which is
      converted to glycerol-3-phosphate and subsequently dihydroxyacetone phosphate (DHAP) in the
      liver. DHAP is converted to fructose-1,6-bisphosphate which undergoes a series of reactions
      to become a single 6-carbon glucose molecule. Adipocytes contribute glycerol to hepatic
      gluconeogenesis through lipolysis of triglyceride stores. Although glycerol-gluconeogenesis
      has been extensively studied in animals, the traditional reliance on radioactive tracers
      makes translation to humans difficult for many reasons. We aim to use new techniques to
      explore the mechanisms behind altered glucose metabolism related to excess visceral adiposity
      in obese adults by quantifying the relative contributions of varying substrates to
      liver-derived glucose. One such method uses 13C3 labeled glycerol to trace the incorporation
      of glycerol from dietary sources to hepatic gluconeogenesis. This technology utilizes nuclear
      magnetic resonance (NMR) spectroscopy, a technique that does not require ionizing radiation
      and has been extensively validated, to analyze the NMR spectra of plasma glucose and quantify
      the &quot;percent enrichment&quot; of the circulating glucose molecules with labeled glycerol. In turn,
      differences in enrichment reflect variability in hepatic glucose metabolism as it relates to
      the contribution of glycerol from visceral adipose tissue to gluconeogenesis.

      The rationale of this project is to utilize existing technology to investigate the impact of
      excess visceral adiposity on glycerol metabolism in hepatic gluconeogenesis in obese adults
      without diabetes and to explore the effects of treatment with EMPA on visceral adiposity
      related glucose homeostasis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">November 2018</completion_date>
  <primary_completion_date type="Actual">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycerol Enrichment</measure>
    <time_frame>3 months</time_frame>
    <description>[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity, Visceral</condition>
  <arm_group>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Empagliflozin 10 mg by mouth daily for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo one tablet daily for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[U-13C3] glycerol</intervention_name>
    <description>Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Glycerine</other_name>
    <other_name>Glycerin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>Active drug</description>
    <arm_group_label>Empagliflozin</arm_group_label>
    <other_name>EMPA</other_name>
    <other_name>Jardiace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Empagliflozin)</intervention_name>
    <description>Placebo tablet manufactured to mimic EMPA 10 mg tablet.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese, defined as BMI â‰¥ 30 kg/m2, at both time of abdominal fat imaging and at study
             entry.

          -  Ages 30-65

          -  No prevalent diagnosis of type 2 diabetes mellitus, either at the time of abdominal
             fat imaging or at study entry.

          -  Previous abdominal fat quantification by magnetic resonance imaging in the Dallas
             Heart Study or possible neck-to-knee MRI for VAT measurement may be performed.

        Exclusion Criteria:

          -  Pregnant or breastfeeding

          -  Incarcerated

          -  Chronic kidney or liver disease

          -  History of frequent (&gt;2/year) urinary tract infections

          -  Non-obese either at time of abdominal fat imaging or at present.

          -  Greater than 10% change in body weight (kg) between time of abdominal fat imaging and
             present.

          -  Has donated blood within last 6 weeks

          -  Cannot give informed consent, understand the protocol, or tolerate any aspect of the
             protocol

          -  If undergoing MRI, persons with metal implants contraindicated for 3Tesla MRI exams
             will be excluded. Severe claustrophobia will also be assessed prior to an MRI exam.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ian Neeland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Neeland IJ, Ayers CR, Rohatgi AK, Turer AT, Berry JD, Das SR, Vega GL, Khera A, McGuire DK, Grundy SM, de Lemos JA. Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity (Silver Spring). 2013 Sep;21(9):E439-47. doi: 10.1002/oby.20135. Epub 2013 May 19.</citation>
    <PMID>23687099</PMID>
  </reference>
  <reference>
    <citation>Neeland IJ, Turer AT, Ayers CR, Powell-Wiley TM, Vega GL, Farzaneh-Far R, Grundy SM, Khera A, McGuire DK, de Lemos JA. Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. JAMA. 2012 Sep 19;308(11):1150-9.</citation>
    <PMID>22990274</PMID>
  </reference>
  <reference>
    <citation>Nurjhan N, Kennedy F, Consoli A, Martin C, Miles J, Gerich J. Quantification of the glycolytic origin of plasma glycerol: implications for the use of the rate of appearance of plasma glycerol as an index of lipolysis in vivo. Metabolism. 1988 Apr;37(4):386-9.</citation>
    <PMID>3357420</PMID>
  </reference>
  <reference>
    <citation>Baba H, Zhang XJ, Wolfe RR. Glycerol gluconeogenesis in fasting humans. Nutrition. 1995 Mar-Apr;11(2):149-53.</citation>
    <PMID>7647479</PMID>
  </reference>
  <reference>
    <citation>Jin ES, Sherry AD, Malloy CR. Interaction between the pentose phosphate pathway and gluconeogenesis from glycerol in the liver. J Biol Chem. 2014 Nov 21;289(47):32593-603. doi: 10.1074/jbc.M114.577692. Epub 2014 Oct 6.</citation>
    <PMID>25288790</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 5, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 14, 2016</study_first_posted>
  <results_first_submitted>February 26, 2019</results_first_submitted>
  <results_first_submitted_qc>April 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 2, 2019</results_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ian Neeland</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Visceral</keyword>
  <keyword>Obesity</keyword>
  <keyword>Adipose</keyword>
  <keyword>Diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
    <mesh_term>Glycerol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD sharing will be done upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_access_criteria>Email the PI with request.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT02833415/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg by mouth daily for 3 months.
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Empagliflozin: Active drug</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo one tablet daily for 3 months
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Placebo (for Empagliflozin): Placebo tablet manufactured to mimic EMPA 10 mg tablet.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg by mouth daily for 3 months.
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Empagliflozin: Active drug</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo one tablet daily for 3 months
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Placebo (for Empagliflozin): Placebo tablet manufactured to mimic EMPA 10 mg tablet.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" lower_limit="43" upper_limit="56"/>
                    <measurement group_id="B2" value="54" lower_limit="48" upper_limit="59"/>
                    <measurement group_id="B3" value="53" lower_limit="46" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126" lower_limit="117" upper_limit="138"/>
                    <measurement group_id="B2" value="132" lower_limit="127" upper_limit="141"/>
                    <measurement group_id="B3" value="130" lower_limit="120" upper_limit="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C</title>
          <units>percent of glycosylated hemoglobin</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.6" lower_limit="5.4" upper_limit="5.9"/>
                    <measurement group_id="B2" value="5.9" lower_limit="5.6" upper_limit="6.1"/>
                    <measurement group_id="B3" value="5.8" lower_limit="5.4" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.8" lower_limit="32.9" upper_limit="38.8"/>
                    <measurement group_id="B2" value="35.3" lower_limit="32.7" upper_limit="39.6"/>
                    <measurement group_id="B3" value="35.5" lower_limit="32.9" upper_limit="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Visceral Fat</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.4" lower_limit="4.0" upper_limit="7.3"/>
                    <measurement group_id="B2" value="4.3" lower_limit="3.8" upper_limit="6.7"/>
                    <measurement group_id="B3" value="5.4" lower_limit="3.9" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycerol Enrichment</title>
        <description>[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Empagliflozin</title>
            <description>Empagliflozin 10 mg by mouth daily for 3 months.
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Empagliflozin: Active drug</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo one tablet daily for 3 months
[U-13C3] glycerol: Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
Placebo (for Empagliflozin): Placebo tablet manufactured to mimic EMPA 10 mg tablet.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycerol Enrichment</title>
          <description>[U-13C3] glycerol enrichment in plasma blood glucose over time will be measured by nuclear magnetic resonance spectroscopy. This is a percentage change from baseline to follow up in the percent enrichment of exogenous glycerol in blood glucose. We are unable to report a measure of central tendency and dispersion as the outcome is a percent change in the area under the enrichment curve for each group between baseline and follow-up. There is no measure of central tendency for these measurements without bootstrapping, which was not performed.</description>
          <units>Percentage change</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5"/>
                    <measurement group_id="O2" value="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Baseline to Followup</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Differences of Least Squares Means</non_inferiority_desc>
            <p_value>0.0053</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Differences of Least Squares Means</param_type>
            <param_value>0.9398</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2941</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Followup</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Differences of Least Squares Means</non_inferiority_desc>
            <p_value>0.5394</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Differences of Least Squares Means</param_type>
            <param_value>0.1520</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.2424</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Adverse Events Definition: Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participantâ€™s participation in the research, whether or not considered related to the participantâ€™s participation in the research.</desc>
      <group_list>
        <group group_id="E1">
          <title>Empagliflozin</title>
          <description>Empagliflozin 10 mg daily by mouth</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo daily by mouth</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ian J. Neeland MD</name_or_title>
      <organization>University of Texas Southwestern Medical Center</organization>
      <phone>214-645-1267</phone>
      <email>ian.neeland@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

